Rinvoq safety study
Treatments studied
Part of Bones, joints & muscles, Digestive system, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study is checking the safety of the medicine Rinvoq (upadacitinib) in people who have been prescribed it. It involves answering a few questions over the phone to help doctors understand how the medicine is working for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been prescribed Rinvoq (upadacitinib) on or after January 1, 2024.
- You must be 18 years old or older.
- You must be willing to give your consent to join the study.
- You must not have severe memory or thinking problems that would prevent you from answering questions over the phone.
- You must not be enrolled in another clinical trial (Phase 1, 2, or 3).
- You must have a life expectancy of more than 1 month and a valid phone number.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how adults with Crohn's disease or ulcerative colitis are doing after taking upadacitinib (Rinvoq) for at least 12 months. It helps doctors understand treatment patterns and outcomes in real-world settings.
This study tests whether the medication upadacitinib (Rinvoq) works similarly for psoriatic arthritis and rheumatoid arthritis. Participants will have ultrasound imaging to track joint inflammation while taking upadacitinib.
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study tests if upadacitinib can reduce episodes of eye inflammation (uveitis) in people with axial spondyloarthritis (a type of inflammatory back arthritis). You may qualify if you've had at least one uveitis flare in the past year and your arthritis is still active despite standard treatments.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
Hear when a new Inflammatory Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.